Ligand Pharmaceuticals Incorporated Congressional Trading
According to U.S. congressional financial disclosures filed under the STOCK Act, members of Congress have reported 11 trades in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) since 2015, across 4 members, worth an estimated $112.50K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts). Democratic members are responsible for 55% of the trades and Republican members 45%. The most recent disclosure shown was filed June 2026, and Gilbert Cisneros has filed the most LGND transactions among those shown, with 4. One notable disclosed move was a purchase by Gilbert Cisneros on January 5, 2026, up 46.7% since. These figures are drawn from public House and Senate periodic transaction reports and reflect what members were required to disclose, not the current market value of any position. Ligand Pharmaceuticals Incorporated's current Quantellect Tide Score is 27 out of 100 (Calm Tide), Bottom 12% of universe (3876); the Tide Score is generated algorithmically from public filings and market data and is not investment advice. For the full record, including the month-by-month buy and sell timeline, the party breakdown, top buyers and sellers, and every individual filing, see the Ligand Pharmaceuticals Incorporated (LGND) stock overview and the complete trade table below.
Data updated
Price & congressional trade timeline
Party breakdown
Ligand Pharmaceuticals congressional trading activity
| Politician | Published | Traded | Filed After | Type | Size | Return | Owner | |
|---|---|---|---|---|---|---|---|---|
 Gilbert Cisneros House | Jun 8, 2026 | May 29, 2026 | 10 days | BUY |  $1,001 - $15,000 | +21.45% | Self | |
Gilbert Cisneros House | Apr 7, 2026 | Mar 3, 2026 | 35 days | BUY | $1,001 - $15,000 | +37.94% | Self | |
Gilbert Cisneros House | Feb 13, 2026 | Jan 15, 2026 | 29 days | BUY | $1,001 - $15,000 | +43.68% | Self | |
Gilbert Cisneros House | Feb 13, 2026 | Jan 5, 2026 | 39 days | BUY | $1,001 - $15,000 | +46.71% | Self |
Ligand Pharmaceuticals (LGND) congressional trading FAQ
Can members of Congress legally trade Ligand Pharmaceuticals (LGND) stock?
Yes. Members of Congress are permitted to trade individual stocks, including Ligand Pharmaceuticals (LGND), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; it does not imply any trade was improper.
Are congressional Ligand Pharmaceuticals (LGND) trades public?
Yes. Every congressional trade in Ligand Pharmaceuticals (LGND) on this page comes from mandatory public STOCK Act disclosure filings, which are filed with a delay and may be revised.
How many times has Congress traded Ligand Pharmaceuticals (LGND)?
Members of Congress have disclosed 11 trades in Ligand Pharmaceuticals (LGND) worth $112.50K across 4 members, according to public STOCK Act filings.
Which members of Congress have traded Ligand Pharmaceuticals (LGND)?
Recent and active filers of Ligand Pharmaceuticals (LGND) disclosures include Gilbert Cisneros. The full member-by-member trade list is on this page.
Do Democrats or Republicans trade Ligand Pharmaceuticals (LGND) more?
Across disclosed Ligand Pharmaceuticals (LGND) trades, 55% were by Democrats and 45% by Republicans, led by Democrats (55%).
What is the most recent congressional Ligand Pharmaceuticals (LGND) trade?
The most recent disclosed Ligand Pharmaceuticals (LGND) trade was a purchase by Gilbert Cisneros, filed Jun 7, 2026.
What is Ligand Pharmaceuticals (LGND)'s Tide Score?
Ligand Pharmaceuticals (LGND) has a Quantellect Tide Score of 27 (Calm Tide). The Tide Score is a 0-100 read blending price forecast, smart-money flow, technicals, and social sentiment; higher is more bullish.
Browse all stocks Congress tradesCongressional trading overviewLigand Pharmaceuticals (LGND) stock overview
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. The Tide Score and other figures are generated algorithmically from public filings and market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.